Ulf is a co-founder of T-CURX. Prior to assuming the role of CEO at T-CURX in 2022, Ulf was CEO and board member at NBE-Therapeutics, a Swiss biotech company that he founded in 2012 and which was focused on the development of antibody-drug conjugates.

Ulf has more than 20 years of experience in founding and building biotechnology companies from the ground up and bringing them to a successful exit. T-CURX is the third biotechnology start-up that Ulf has co-founded. Prior to T-CURX, he co-founded 4-Antibody AG, Basel, Switzerland, which was sold to U.S.-based Agenus in 2014, and NBE-Therapeutics, which was sold to Boehringer Ingelheim in 2021. At both companies, Ulf raised over €90 million in venture funding, and he was instrumental in negotiating commercial agreements worth over €1 billion in aggregate deal volume.

Ulf holds a Diploma in Biochemistry from the University of Bayreuth, Germany, and obtained his PhD from the University of Basel in 1994 for work performed at the Basel Institute for Immunology, a research institute associated with three Nobel Prizes.

After his PhD, he performed several years of post-doctoral research in the U.S., at both Washington University School of Medicine in St. Louis, MO, and the University of Southern California (USC) in Los Angeles, CA. After his post-doctoral research in the U.S., he returned to Europe to become a principal investigator at the Basel Institute for Immunology, Switzerland, the University of Ulm, Germany, and the University of Basel, Switzerland.

Ulf has published over 40 peer-reviewed papers in immunology and cell biology, and he is an inventor on 15 granted and pending patents. Ulf also serves on the boards of public and private companies (Adagene, NASDAQ: ADAG; WuXi XDC, HKEX: 2268; and AUM Bioscience, a private company based in Singapore). Ulf also holds a diploma in Technology Entrepreneurship from the Executive School of Management, Technology and Law of the University of St. Gallen, Switzerland.